A new treatment approach combining immunotherapy with laser heat therapy may significantly extend the survival of individuals diagnosed with deadly brain cancers, according to researchers at Keck Medicine, University of Southern California (USC). The findings, which offer new hope for patients with limited treatment options, were announced in a press release highlighting the potential of this combination therapy.
Entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are engaged in developing treatments for brain cancers may benefit from these developments. The study underscores the growing interest in leveraging the body’s immune system alongside advanced technologies to combat aggressive tumors.
Immunotherapy works by stimulating the immune system to recognize and attack cancer cells, while laser heat therapy, also known as laser interstitial thermal therapy (LITT), uses heat to destroy tumor tissue. The combination appears to enhance the immune response, potentially leading to longer survival times for patients with glioblastoma and other deadly brain tumors.
The research, conducted at Keck Medicine of USC, represents a significant step forward in the fight against these malignancies, which have historically poor prognoses. Standard treatments such as surgery, radiation, and chemotherapy often provide limited benefit, underscoring the need for innovative approaches.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @IBN and provides services including press release distribution, article syndication, and social media amplification to help companies reach investors and the public.
While the findings are preliminary, they offer a promising avenue for future clinical trials and potential treatment options. Patients and healthcare providers are encouraged to stay informed about ongoing research in this area. For more information, visit BioMedWire’s disclaimer page for terms of use.
